{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:40:08Z","timestamp":1771483208626,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.brachy.2017.12.005","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T20:25:43Z","timestamp":1517603143000},"page":"530-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase II trial of 8\u00a0weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery"],"prefix":"10.1016","volume":"17","author":[{"given":"M.A.","family":"Korzeniowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bowes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gazta\u00f1aga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jazwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"T\u00e9treault-Laflamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pilote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-2080","authenticated-orcid":false,"given":"D.","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bachand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2017.12.005_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2010.04.038","article-title":"10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients","volume":"80","author":"Crook","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5 Suppl","key":"10.1016\/j.brachy.2017.12.005_bib3","first-page":"S20","article-title":"12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer","volume":"179","author":"Potters","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2017.12.005_bib4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2009.10.035","article-title":"Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy","volume":"79","author":"Martinez","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2017.12.005_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0360-3016(99)00176-5","article-title":"Urinary morbidity following ultrasound-guided transperineal prostate seed implantation","volume":"45","author":"Gelblum","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.urology.2007.04.042","article-title":"Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy","volume":"70","author":"Mabjeesh","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2017.12.005_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0360-3016(98)00459-3","article-title":"Use of TRUS to predict pubic arch interference of prostate brachytherapy","volume":"43","author":"Wallner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(99)00119-4","article-title":"The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate","volume":"44","author":"Whittington","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/S0022-5347(05)65001-X","article-title":"Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy","volume":"167","author":"Kucway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2017.12.005_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ijrobp.2004.01.017","article-title":"Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy","volume":"59","author":"Hinerman-Mulroy","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0936-6555(03)00093-1","article-title":"Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study","volume":"15","author":"Henderson","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2017.12.005_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.juro.2006.10.018","article-title":"The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume","volume":"177","author":"Stone","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2017.12.005_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00130404-200411000-00003","article-title":"Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression","volume":"10","author":"Solhjem","year":"2004","journal-title":"Cancer J"},{"issue":"1 Suppl","key":"10.1016\/j.brachy.2017.12.005_bib18","first-page":"S34","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"189","author":"Saylor","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2017.12.005_bib19","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2004-1158","article-title":"Endogenous sex hormones and metabolic syndrome in aging men","volume":"90","author":"Muller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.brachy.2017.12.005_bib20","series-title":"Duration of androgen deprivation therapy in high risk prostate cancer: final results of a randomized phase III trial","year":"2017"},{"key":"10.1016\/j.brachy.2017.12.005_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2008.04.075","article-title":"Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer","volume":"73","author":"Crook","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2017.12.005_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2015.11.022","article-title":"Randomized noninferiority trial of bicalutamide and dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer","volume":"118","author":"Gaudet","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2017.12.005_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2006.01.061","article-title":"Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy","volume":"68","author":"Merrick","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2017.12.005_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.0919-8172.2003.00601.x","article-title":"Neoadjuvant flutamide monotherapy for locally confined prostate cancer","volume":"10","author":"Yoshimura","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.brachy.2017.12.005_bib25","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2017.12.005_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.prnil.2015.02.005","article-title":"Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study","volume":"3","author":"You","year":"2015","journal-title":"Prostate Int"},{"key":"10.1016\/j.brachy.2017.12.005_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"Mason","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2017.12.005_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","article-title":"Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief, and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide","volume":"110","author":"Axcrona","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2017.12.005_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2017.12.005_bib30","doi-asserted-by":"crossref","first-page":"e109346","DOI":"10.1371\/journal.pone.0109346","article-title":"A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years","volume":"9","author":"Kelsey","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.brachy.2017.12.005_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1464-410X.2006.06013.x","article-title":"Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer","volume":"97","author":"Murthy","year":"2006","journal-title":"BJU Int"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472117305743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472117305743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:12:53Z","timestamp":1761531173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472117305743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1538472117305743"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2017.12.005","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II trial of 8\u00a0weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2017.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}